Header Logo

Connection

CHRISTIE BALLANTYNE to Eicosapentaenoic Acid

Back to Details
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Eicosapentaenoic Acid.
CHRISTIE BALLANTYNE
Connection Strength
7.036
Eicosapentaenoic Acid
  1. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019 01 03; 380(1):11-22.
    View in: PubMed
    Score: 0.592
  2. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. Atherosclerosis. 2016 10; 253:81-87.
    View in: PubMed
    Score: 0.508
  3. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. J Clin Lipidol. 2016 May-Jun; 10(3):635-645.e1.
    View in: PubMed
    Score: 0.491
  4. Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study). J Clin Lipidol. 2015 May-Jun; 9(3):377-83.
    View in: PubMed
    Score: 0.451
  5. Icosapent ethyl for the treatment of hypertriglyceridemia. Expert Opin Pharmacother. 2013 Jul; 14(10):1409-16.
    View in: PubMed
    Score: 0.406
  6. Authors' reply. Am J Cardiol. 2013 Feb 01; 111(3):455-6.
    View in: PubMed
    Score: 0.397
  7. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025 Mar 04; 14(5):e038656.
    View in: PubMed
    Score: 0.229
  8. Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial. Eur Heart J. 2024 Apr 01; 45(13):1173-1176.
    View in: PubMed
    Score: 0.215
  9. Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl. J Am Coll Cardiol. 2024 Apr 23; 83(16):1529-1539.
    View in: PubMed
    Score: 0.215
  10. Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. JAMA Netw Open. 2022 02 01; 5(2):e2148172.
    View in: PubMed
    Score: 0.185
  11. Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT. J Am Coll Cardiol. 2022 01 18; 79(2):220-222.
    View in: PubMed
    Score: 0.185
  12. Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. Circulation. 2021 11 30; 144(22):1750-1759.
    View in: PubMed
    Score: 0.182
  13. Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. Circulation. 2021 12 07; 144(23):1845-1855.
    View in: PubMed
    Score: 0.182
  14. Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. J Am Coll Cardiol. 2021 10 12; 78(15):1525-1537.
    View in: PubMed
    Score: 0.181
  15. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020 12 08; 324(22):2268-2280.
    View in: PubMed
    Score: 0.171
  16. Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses. Circulation. 2021 01 05; 143(1):33-44.
    View in: PubMed
    Score: 0.170
  17. JCL roundtable: Omega-3 fatty acids and cardiovascular outcomes. J Clin Lipidol. 2020 Jan - Feb; 14(1):4-15.
    View in: PubMed
    Score: 0.160
  18. Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles. J Am Coll Cardiol. 2019 08 27; 74(8):1159-1161.
    View in: PubMed
    Score: 0.157
  19. Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides. Postgrad Med. 2019 Aug; 131(6):390-396.
    View in: PubMed
    Score: 0.156
  20. Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study). Am J Cardiol. 2019 09 01; 124(5):696-701.
    View in: PubMed
    Score: 0.154
  21. Effects of Icosapent Ethyl on Total?Ischemic Events: From REDUCE-IT. J Am Coll Cardiol. 2019 06 11; 73(22):2791-2802.
    View in: PubMed
    Score: 0.152
  22. Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial. Circulation. 2019 03 05; 139(10):1341-1343.
    View in: PubMed
    Score: 0.151
  23. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis. J Womens Health (Larchmt). 2018 09; 27(9):1170-1176.
    View in: PubMed
    Score: 0.142
  24. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. Clin Cardiol. 2017 Mar; 40(3):138-148.
    View in: PubMed
    Score: 0.132
  25. Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials). Am J Cardiol. 2017 Feb 01; 119(3):397-403.
    View in: PubMed
    Score: 0.129
  26. Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. Prostaglandins Other Lipid Mediat. 2016 09; 125:57-64.
    View in: PubMed
    Score: 0.126
  27. Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome. Metab Syndr Relat Disord. 2015 Aug; 13(6):239-47.
    View in: PubMed
    Score: 0.116
  28. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. Cardiovasc Diabetol. 2013 Jul 09; 12:100.
    View in: PubMed
    Score: 0.102
  29. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs. 2013 Feb; 13(1):37-46.
    View in: PubMed
    Score: 0.099
  30. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). J Clin Lipidol. 2012 Nov-Dec; 6(6):565-72.
    View in: PubMed
    Score: 0.096
  31. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011 Sep 01; 108(5):682-90.
    View in: PubMed
    Score: 0.089
  32. Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1?, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy. Circulation. 2022 08 02; 146(5):372-379.
    View in: PubMed
    Score: 0.048
  33. Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior?Myocardial Infarction. J Am Coll Cardiol. 2022 05 03; 79(17):1660-1671.
    View in: PubMed
    Score: 0.047
  34. Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT. J Am Heart Assoc. 2022 04 05; 11(7):e024999.
    View in: PubMed
    Score: 0.047
  35. Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI. J Am Heart Assoc. 2022 03 15; 11(6):e022937.
    View in: PubMed
    Score: 0.047
  36. A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study. J Am Heart Assoc. 2022 03 15; 11(6):e024176.
    View in: PubMed
    Score: 0.047
  37. Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions. Curr Atheroscler Rep. 2020 06 03; 22(7):25.
    View in: PubMed
    Score: 0.041
  38. REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States. Circulation. 2020 02 04; 141(5):367-375.
    View in: PubMed
    Score: 0.040
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.